Is retatrutide more effective than tirzepatide?
Phase 2 retatrutide data shows higher weight loss than tirzepatide Phase 3, but cross-trial comparisons are unreliable. No head-to-head trial exists yet.
Updated May 20, 2026 · 4 min read
The honest answer is: we don't know yet. The early data is more impressive for retatrutide, but that data comes from a Phase 2 trial versus tirzepatide's Phase 3 data — an apples-to-oranges comparison that can't establish which drug is actually superior. No head-to-head trial exists.
What the Numbers Show
The most-cited comparison starts with these two numbers:
- Tirzepatide (SURMOUNT-1, Phase 3): mean body weight loss of 20.9% at 72 weeks at the 15 mg dose
- Retatrutide (Phase 2 trial, Jastreboff et al., 2023): mean body weight loss of approximately 24.2% at 48 weeks at the 24 mg dose
On the surface, 24.2% > 20.9%, so retatrutide looks more effective.
But the comparison has significant problems.
Why You Can't Compare These Numbers Directly
Phase 2 vs Phase 3. Phase 2 trials are small, run in highly controlled conditions, and tend to show better results than Phase 3 — which recruits a larger, more diverse population with less intensive monitoring. The history of drug development is littered with Phase 2 results that didn't replicate in Phase 3. Retatrutide's Phase 3 TRIUMPH trials are ongoing, and the results may be somewhat lower.
Different trial durations. Tirzepatide's 20.9% came at 72 weeks. Retatrutide's 24.2% came at 48 weeks — a shorter window. GLP-1 weight loss continues to accrue over time as patients titrate up and sustain the medication. Tirzepatide at 48 weeks shows less than 20.9%; retatrutide at 72 weeks would likely show more than 24.2%. The endpoints don't line up.
Different populations. SURMOUNT-1 was a Phase 3 trial with pre-specified entry criteria and a large, heterogeneous global population. The retatrutide Phase 2 trial enrolled a smaller, more homogeneous group. Population differences affect outcomes.
Different doses. The retatrutide number cited is from the 24 mg dose. The tirzepatide number is from 15 mg — which is tirzepatide's maximum approved dose. The doses aren't inherently equivalent just because they're each the maximum in their respective trials.
What Retatrutide Adds: The Glucagon Mechanism
Retatrutide is a triple agonist — it activates GLP-1, GIP, and glucagon receptors. The glucagon activation is the new piece. Where semaglutide is GLP-1 only and tirzepatide is GLP-1 plus GIP, retatrutide adds a receptor that drives energy expenditure by activating thermogenic pathways in the liver and adipose tissue.
This thermogenic component is the theoretical basis for retatrutide's weight-loss advantage. If it holds in Phase 3, it would represent a meaningful mechanistic difference — not just a more potent version of what tirzepatide does, but a drug that works through a partly different pathway.
Whether that mechanistic difference translates into a reliably superior clinical outcome for real patients is what the TRIUMPH Phase 3 trials are designed to determine. Until those results are published, the advantage is inferred from mechanism, not established from outcomes data.
The Most Honest Summary
| Tirzepatide | Retatrutide | |
|---|---|---|
| Phase 3 data | Yes (SURMOUNT-1–4) | No (TRIUMPH ongoing) |
| Max weight loss in trials | ~20.9% at 72 weeks | ~24.2% at 48 weeks (Phase 2) |
| FDA approved | Yes (Mounjaro, Zepbound) | No |
| Mechanism | GLP-1 + GIP | GLP-1 + GIP + glucagon |
| Head-to-head data | — | None |
If the question is "what can I get today that has the most Phase 3-backed evidence for weight loss," tirzepatide at 15 mg is the answer. If the question is "which drug might show the best results when retatrutide's Phase 3 data comes in," the early signals favor retatrutide — but that's a prediction, not a fact.
What This Means Practically
Tirzepatide is available now. Retatrutide is not.
If tirzepatide at your current dose is working, there's no rationale for waiting. If you're not getting the results you hoped for on tirzepatide — particularly if you've reached the 15 mg maintenance dose and are still not hitting your goals — retatrutide represents a potential future option, assuming its Phase 3 results are positive and FDA approval follows.
The people who will get the most direct benefit from retatrutide, if it approves, are likely those who've exhausted or maximized tirzepatide and need a different pharmacological mechanism. There's less basis to claim it would be meaningfully better for the average person starting treatment from scratch — especially given how different real-world Phase 3 results often look from Phase 2.